Dimerix Ltd has surged by 31% as a result of a significant announcement of a partnership with FUSO Pharmaceutical Industries in Japan. This exclusive collaboration focuses on the development and commercialization of DMX-200, a promising drug candidate targeting FSGS, a kidney disease. FUSO will lead the efforts in Japan and provide financial support for the development, regulatory, and commercial initiatives.
Company Information
Company
Dimerix Limited
Location
Melbourne, Victoria, Australia
About
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets.
Dimerix is currently developing its proprietary product, DMX-200, for kidney diseases and for respiratory complications associated with COVID-19.
Dimerix has three Phase 3 clinical programs with near term value propositions
1) Global Phase 3 REMAP-CAP study in at least 200 hospitalised COVID-19 patients with respiratory pneumonia in Europe and UK
2) Multi-national Phase 3 CLARITY 2.0 study in at least 600 COVID-19 patients with respiratory complications in India
3) Global Phase 3 study in Focal Segmental Glomerulosclerosis (FSGS) patients, which is a rare kidney disease, following positive Phase 2 data in 2020 and for which Dimerix has been granted Orphan Drug Designation by the FDA and EMA
Dimerix also has longer term programs in Diabetic Kidney Disease and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).
MelbourneBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma